SCNX
Scienture Holdings, Inc.0.5500
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
22.35MP/E (TTM)
0.73Basic EPS (TTM)
0.75Dividend Yield
0%Recent Filings
10-K
FY2025 results
Scienture Holdings posted FY2025 revenues of $432K from Q3/Q4 ARBLI™ (SCN-102) launch post-FDA approval, up 216% y/y yet representing early commercialization ramp. Q4 drove all topline amid pipeline investments, but $26.3M non-cash impairments wiped goodwill and IPR&D values for SCN-104/106/107 as market cap plunged below book value. Operating loss swelled to $42.6M on $16.6M opex (ex-impairment) reflecting sales buildout, offset by $19.7M equity raises bolstering $6.7M cash and $5.2M working capital. No debt remains; Tollo note yields steady interest. Clinical delays threaten Q4 momentum.
8-K
Revised investor presentation posted
Scienture Holdings posted a revised investor presentation on November 17, 2025, under Item 7.01, for use in upcoming analyst and investor meetings. It features forward-looking statements on projects, financial performance, and growth, furnished not filed. Risks detailed in SEC filings could alter outcomes.
8-K
Split AGM votes on shares
Scienture Holdings' stockholders elected all five director nominees at its November 12, 2025 annual meeting, with 52% quorum. They approved boosting the 2019 Plan share pool to 25M shares, future discounted offerings over 20% of outstanding stock, and board discretion for a 1:2 to 1:50 reverse split—but rejected expanding authorized common shares to 2B. Mixed signals on dilution.
8-K
Boosts ATM offering to $150M
10-Q
Q3 FY2025 results
Scienture Holdings ramped revenue to $590K in Q3 ended September 30, 2025, up sharply from $65K y/y, with gross profit hitting 97% thanks to SCN-102 losartan sales—yet operating loss widened to $4.4M from $3.5M y/y amid elevated professional fees, accounting/legal, and G&A from equity issuances. Net loss from continuing ops narrowed to $3.6M ($0.19/share) vs $3.2M ($1.34/share) y/y, boosted by $2.4M derivative gain and $59K warrant gain, though interest expense jumped on debt amortization; EPS aligns with 19M diluted shares. Cash ticked to $356K while operating cash burn eased to $8.2M YTD; $2M Scienture debt (15.5%, due Sep 2025) and $5M note receivable loom large. Cash stays tight.
BHIC
-
4.00+0.00
BSX
Boston Scientific Corporation
92.95+0.76
CPHI
China Pharma Holdings, Inc.
1.44-0.09
CVSI
CV Sciences, Inc.
0.03+0.00
LXRX
Lexicon Pharmaceuticals, Inc.
1.20-0.03
SCLX
Scilex Holding Company
15.76-0.76
SCPH
scPharmaceuticals Inc.
5.67+0.00
SMNR
Semnur Pharmaceuticals Inc.
9.00+0.00
SXTC
China SXT Pharmaceuticals, Inc.
1.64+0.19
WGRX
Wellgistics Health, Inc.
0.54-0.04